Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: a retrospective cohort study by Quinn, Frederick et al.
RESEARCH ARTICLE
Translating drug resistant tuberculosis
treatment guidelines to reality in war-torn
Kandahar, Afghanistan: A retrospective cohort
study
Anita MesicID1*, Waliullah H. Khan2, Annick Lenglet1,3, Lutgarde Lynen4,
Sadiqqulah Ishaq5, Ei Hnin Hnin Phyu5, Htay Thet Mar5, Anthony Oraegbu5, Mohammad
Khaled Seddiq6, Hashim Khan Amirzada6, Jena Fernhout1, Charity Kamau1, Cono Ariti7,
Diana Gomez1, Tom Decroo4,8
1 Me´decins Sans Frontières, Amsterdam, The Netherlands, 2 Me´decins Sans Frontières, Islamic Republic of
Afghanistan, Kabul, Afghanistan, 3 Department of Medical Microbiology, Radboudumc, Nijmegen, The
Netherlands, 4 Institute of Tropical Medicine Antwerp, Antwerp, Belgium, 5 Me´decins Sans Frontières,
Islamic Republic of Afghanistan, Kandahar, Afghanistan, 6 National Tuberculosis Control Programme,
Islamic Republic of Afghanistan, Kabul, Afghanistan, 7 Centre for Trials Research, Cardiff University Medical
School, Cardiff, United Kingdom, 8 Research Foundation Flanders, Brussels, Belgium
* anita.mesic@amsterdam.msf.org
Abstract
Introduction
Afghanistan is affected by one of the world’s longest protracted armed conflicts, frequent
natural disasters, disease outbreaks and large population movements and it suffers from a
high burden of tuberculosis (TB), including rifampicin-resistant TB (RR-TB). The study
shows Me´decins Sans Frontières’ experiences with care for patients with RR-TB in Kanda-
har Province. We describe the uptake of RR-TB treatment, how World Health Organisation
criteria for the choice between the short and an individualized regimen were implemented,
and treatment outcomes.
Methods
This is a retrospective cohort analysis of routinely collected data from RR-TB patients
enrolled in care from 2016 until 2019. Descriptive analysis was performed to present charac-
teristics of patients and treatment outcomes. Multivariable Cox analysis was performed to
identify risk factors for having an unfavourable treatment outcome.
Results
Out of 146 enrolled RR-TB patients, 112 (76.7%) started treatment: 41 (36.6%) and 71
(63.4%) with the short and individualized treatment regimen, respectively. Of 82 with results
for fluoroquinolone susceptibility, 39 (47.6%) had fluoroquinolone-resistant TB. Seven
patients with initially fluoroquinolone-resistant TB and three pregnant women started the
short regimen and 18 patients eligible for the short regimen started the injectable-free
PLOS ONE
PLOS ONE | https://doi.org/10.1371/journal.pone.0237787 August 21, 2020 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Mesic A, Khan WH, Lenglet A, Lynen L,
Ishaq S, Hnin Phyu EH, et al. (2020) Translating
drug resistant tuberculosis treatment guidelines to
reality in war-torn Kandahar, Afghanistan: A
retrospective cohort study. PLoS ONE 15(8):
e0237787. https://doi.org/10.1371/journal.
pone.0237787
Editor: Frederick Quinn, The University of Georgia,
UNITED STATES
Received: June 16, 2020
Accepted: July 31, 2020
Published: August 21, 2020
Copyright: © 2020 Mesic et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data are available on
request. MSF has a managed access system for
data sharing that respects MSF’s legal and ethical
obligations to its patients to collect, manage and
protect their data responsibility. Ethical risks
include, but are not limited to the nature of MSF
operations and target populations being such that
data collected often involves highly sensitive data.
The dataset supporting the conclusions of this
article is available are available on request in
accordance with MSF’s data sharing policy
individualized regimen. Overall, six-month smear and culture conversion were 98.7% and
97.1%, respectively; treatment success was 70.1%. Known initial fluoroquinolone resis-
tance (aHR 3.77, 95%CI:1.53–9.27) but not choice of regimen predicted having an unfa-
vourable outcome.
Conclusion
Even though criteria for the choice of treatment regimen were not applied strictly, we have
achieved acceptable outcomes in this cohort. To expand RR-TB care, treatment regimens
should fit provision at primary health care level and take patient preferences into account.
Introduction
Tuberculosis (TB) is the most important infectious disease in terms of global mortality and
also a major cause of death related to antimicrobial resistance [1]. Access to care for persons
with drug-resistant tuberculosis is limited and treatment outcomes in these patients are far
from satisfactory. In 2018, there were 484,000 people with rifampicin-resistant (RR-TB), but
only one-third was enrolled on treatment. Only 56% of those with RR-TB for whom outcomes
were reported in 2018 were treated successfully [1].
Afghanistan has a population of over 37 million people [2] and is affected by one of the
world’s longest protracted armed conflicts, frequent natural disasters, disease outbreaks and
large population movements. In 2018, it was estimated that almost 2 million people were in
need of humanitarian medical services [3]. The provision of medical care is hugely challenging,
as exemplified by 85 registered attacks on health care facilities in 2018 [3]. Despite this chal-
lenging context, the National Tuberculosis Control Programme (NTP) decentralized TB ser-
vices as part of the Basic Package of Health Services since 2005 [4].
In Afghanistan TB incidence is estimated at 189 per 100,000 population per year. About 3%
(95%CI 1.4–5.3) and 12% (95%CI 11–14%) of new and retreatment cases have RR-TB, respec-
tively. An estimated 2,500 (95%CI 1,000–4,700) patients developed RR-TB in Afghanistan in
2018 [5]. The diagnosis of RR-TB has increased since the roll-out of Xpert1MTB/RIF (Xpert;
Cepheid, Sunnyvale, CA, USA), a rapid molecular test, now available in 68 sites in the country.
Access to second-line line probe assay (SL-LPA; GenoType MTBDRsl; Hain Lifesciences, Neh-
ren, Germany) testing is limited, as this test is not yet regularly performed at the National TB
Reference Laboratory in Kabul. Patients diagnosed with RR-TB are usually treated with a stan-
dardized long (20-months or more) treatment regimen. RR-TB treatment is currently available
in five provinces (Kabul, Balkh, Herat, Nangarhar, Kandahar). Barriers to care include lack of
quality assured laboratory services, lack of qualified health staff at the health facility, insecurity,
cultural barriers, and TB related stigma [3].
Since 2016, in Kandahar, Me´decins Sans Frontières (MSF) used either a short treatment
regimen (STR), as recommended in the 2016 WHO Guidelines [6] and described in the
national guideline [7], or an individualized long regimen, taking into account drug susceptibil-
ity testing (DST) results, previous exposure to TB drugs, age, concomitant treatment and
comorbidities. We adapted 2016 WHO criteria to decide if a patient would be treated with
either the short or long RR-TB treatment regimen. Previously analyses used data on TB drug
resistance prevalence to calculate the proportion of patients eligible for the STR, which ranged
between 10 and 51% [8–13]. However, since the 2016 WHO criteria were published, no previ-
ous study described in detail how these criteria were translated to the operational reality of a
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TB programme. We therefore describe characteristics and treatment outcomes of patients
started on RR-TB treatment, by regimen in Kandahar since 2016. Moreover, we estimate pre-
dictors for having an unfavourable treatment outcome.
Methods
Design and study population
This is a retrospective cohort study of all patients started on RR-TB treatment in Kandahar,
Afghanistan, between 22nd October 2016 and 18th November 2019. The study observation
period ended on 20th March 2020.
Study setting
Kandahar province has a population of approximately 1,200,000 people. Due to conflict and
insecurity health care actors are sparse. In close collaboration with the Kandahar Provincial
Health Directorate (PHD) and the NTP, MSF supports diagnosis and treatment of patients
with drug-sensitive TB in the Regional Merwaiz Hospital and Provincial TB Center Kandahar.
Patients diagnosed with RR-TB on Xpert MTB/RIF are referred to the MSF RR-TB facility.
Bacteriological investigations
From patients with RR-TB, specimens are collected before treatment initiation and sent to the
Institute of Tropical Medicine Antwerp in Belgium (ITM; Supra-National Reference Tubercu-
losis Laboratory), where SL-LPA together with phenotypic resistance testing are performed.
Results of molecular testing are obtained after about three weeks. During treatment, monthly
specimens are collected for smear microscopy performed in Kandahar and culture at the ITM.
Choice of treatment regimen
Patients should start treatment within one week after RR-TB diagnosis. Exclusion criteria for
the STR were adapted from the 2016 WHO criteria and were: known initial resistance to fluo-
roquinolones, more than one month previous exposure to second-line TB drugs, age below 15
years (limited capacity to perform audiometry in children), pregnancy or having a medical
contraindication to any of the drugs in the regimen. The patient’s preference for either the
individualized or short regimen was also taken into account. In contrast with the 2016 WHO
criteria, initial resistance to drugs other than fluoroquinolone was not an exclusion criterium
for using the STR [6]. While waiting for the results of SL-LPA testing, those without exclusion
criteria were initiated on the STR. When SL-LPA results arrived and showed resistance to
either fluoroquinolone or injectables, the treatment regimen was individualized. Those not eli-
gible, not preferring or not tolerating the STR received the individualized (20+) long regimen
following the national and WHO guidelines, including new (bedaquiline, delamanid) and
repurposed drugs (linezolid, clofazimine, imipenem).
Clinical management and follow-up
Ambulatory treatment was preferred and only clinically unstable patients were hospitalised at
the MSF RR-TB facility. Daily administration of second-line injectables and monthly follow-
up visits were organised at the outpatient department of the same facility. For almost all
patients, oral treatment was self-administered (SAT), and supported by a family member or
other caretaker. For patients coming from outside of Kandahar city MSF provided accommo-
dation, which could be utilized throughout their treatment, during the intensive phase with
daily administration of injections, or for a short stay during monthly follow-up visits. All travel
PLOS ONE Implementing drug resistant tuberculosis treatment guidelines in Kandahar, Afghanistan
PLOS ONE | https://doi.org/10.1371/journal.pone.0237787 August 21, 2020 3 / 17
expenses for patients and their caretakers were reimbursed by MSF. We systematically moni-
tored patients for adverse events (AE), which were managed based on the EndTB clinical
guidelines [14]. Severe adverse events (SAE) were reported to the national programme as part
of the Active Tuberculosis Drug-Safety Monitoring and Management (aDSM) guidance from
the WHO [15]. Psychosocial support was part of the care package and included counselling
sessions by trained counsellors and participation in a peer support group during follow-up vis-
its in the clinic. For patients on SAT who had access to a telephone, weekly phone calls with
the counsellor were organized to provide adherence support and to monitor adverse events.
Systematically post-treatment monitoring was done for a duration of one year, including
a clinical assessment and bacteriological and radiological investigations in those with
symptoms.
Contact tracing
All close household contacts were screened for the presence of TB symptoms. In addition, all
children under the age of five and all symptomatic contacts had a chest radiography and were
asked to provide a sputum sample for bacteriological analysis. Clinical assessment of contacts
was done at the start of treatment of the index case and then every 3 months. Travel expenses
for contacts were reimbursed.
Data collection and analysis
The study used routine programme data collected from standardized patient forms and
retrieved from the MSF TB programme database (named Koch6). The dataset was exported
into statistical software STATA (version 14.2, Texas, USA) for statistical analysis. Independent
variables included age, gender, marital status, employment, province of origin, radiological
severity, case definition, body mass index (BMI), co-morbidities, drug-resistance, and treat-
ment regimen. Case and treatment outcome definitions followed the WHO recommendations
[16]. Death, lost to follow-up (LFU) or treatment failure were considered as unfavourable
treatment outcomes.
All patients that initiated RR-TB treatment were included in the descriptive analysis. Cate-
gorical variables were summarized using frequencies and percentages. Continuous variables
were summarized using medians and interquartile ranges (IQRs). BMI (<18.5 kg/m2,�1 18.5
kg/m2) and age (�15, >15 years) were categorized. Categorical variables marital status (with a
partner/without a partner) and employment (employed/not employed) were dichotomized.
Radiological severity on chest radiography included the following categories: normal (no path-
ological changes detected), non-severe (unilateral pathological changes detected but no cavities
present) and severe (cavity(s) and/or bilateral disease). The chi-squared test was used to assess
whether baseline characteristics were associated with pre-treatment attrition (either LFU or
death). The chi-squared test was used to assess differences in proportions between both
cohorts (STR vs individualized regimen). Patients with a treatment outcome were included in
the Cox univariate and multivariate regression analysis. Unadjusted hazard ratios (HR) with
their 95%CI were calculated to assess if independent variables were associated with having an
unfavourable outcome. Independent variables with p<0.10 in univariate analysis and potential
confounders (province of origin, regimen) were included in the final multivariable model
regardless of the p-value. In patients with a positive initial smear/culture result and who started
treatment at least 4 months before the end of the study period Kaplan Meier survival curves
were plotted to show time to smear/culture conversion by regimen. The log-rank test was used
to test significance of differences between strata according to the regimen.
PLOS ONE Implementing drug resistant tuberculosis treatment guidelines in Kandahar, Afghanistan
PLOS ONE | https://doi.org/10.1371/journal.pone.0237787 August 21, 2020 4 / 17
Ethical approval
The study was approved by the Institutional Review Board, Ministry of Public Health Afghani-
stan (A07190052) and fulfilled the exemption criteria set by the MSF independent Ethical
Review Board [17] for a posteriori analyses of routinely collected clinical data and thus did not
require MSF ERB review. It was conducted with permission from the MSF Medical Director,
Operational Center Amsterdam. All data used for the study originated from the medical rec-
ords of the MSF RR-TB facility and were fully anonymized before making them available for
the analysis. Data were analysed between20 March and 15 May 2020.
Results
Enrolment on RR-TB treatment
During the study period (2016–2019) 146 RR-TB patients enrolled in care at the MSF RR-TB
facility (Fig 1). Of the 146 patients, 112 (76.7%) started treatment during the study period. Of
the 34 (30.3%) patients that did not start on treatment, 25 (73.5%) refused treatment, 8
(23.5%) died before starting treatment and one (3.0%) expressed preference for treatment out-
side Afghanistan.
Similar proportions of female and male patients started treatment (77.3% (68/88) in females
vs. 75.9% (44/58) in males). Similar proportions of patients from both inside and outside of
Kandahar province started treatment (75.3% (67/89) from outside Kandahar vs 78.9% (45/57)
from inside Kandahar). All children (n = 16) diagnosed with RR-TB were initiated on treat-
ment. Treatment initiation was more likely in patients that reported contact with an existing
RR-TB case (96.0% (24/25) with contact vs. 72.7% (88/121) without contact history; p = 0.02).
Patients with a positive baseline smear result were also more likely to start the treatment com-
pared to those with a negative smear (80.9% (89/110) vs. 60.0% (18/30); p = 0.02). Patients
with a positive baseline culture result were more likely to start the treatment compared to
those with a negative culture (93.1% (81/87) vs. 70.3% (26/37); p<0.01).
Fig 1. Kandahar cohort flowchart.
https://doi.org/10.1371/journal.pone.0237787.g001
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Baseline characteristics
Among 112 patients that started on treatment, 67 (59.8%) originated from outside Kandahar
province, 68 (60.7%) were female; and the median age was 32.2 years (IQR 21.1–39.7).
Twenty-four patients were diagnosed after contact tracing (21.5%), including five (63%) of
eight patients under five years of age. About half of the patients (48.2%) were not previously
treated for TB. The baseline demographic characteristics were similar for patients started on
STR and individualized treatment regimen (Table 1).
Of the 112 patients that started on treatment, 68 (60.7%) were undernourished when start-
ing treatment, 95 (84.2%) had severe disease on chest radiography, 62 (55.3%) had cavitary
lung disease, 89 (79.5%) were smear-positive and 81 (72.3%) were culture-positive at baseline.
Only 3 patients had extrapulmonary TB (EPTB: two with meningitis and one with osteoarticu-
lar EPTB. Of 93 (83.0% of 112) with a baseline hearing status recorded, 49 (52.6%) had some
hearing loss before starting RR-TB treatment. Baseline disease characteristics were similar for
both treatment regimen cohorts (Table 2).
Baseline isoniazid DST results were missing for 28 (25%) patients. Of 81 (72.3%) with LPA
results, katG and inhA mutations were identified in 33 (40.7%) and 8 (9.9%) of patients,
respectively, and only 2 (2.4%) patients had mutations in both genes. Of 43 (38.4%) patients
with baseline pyrazinamide DST results, 20 (46.5%) had TB resistant to pyrazinamide. The fre-
quency of initial resistance to isoniazid and pyrazinamide was similar for both treatment regi-
men cohorts (Table 3). Of 82 patients with fluoroquinolone DST results, 39 (47.6%) had
Table 1. Demographic characteristics of patients enrolled in RR-TB care, by treatment.
Characteristic Treatment not
started (n = 34)
Treatment started (n = 112)
Short treatment
regimen (n = 41)
Individualized
regimen (n = 71)
p-Valuea
N % N % N %
Geographical origin 0.07
Kandahar province 12 35.3 21 51.2 24 33.8
Another province 22 64.7 20 48.8 47 66.2
Gender 0.24
Male 14 41.2 19 46.3 25 35.2
Female 20 58.8 22 53.7 46 64.8
Age groups 0.63
Age <15 0 5 12.2 11 11.5
Age = > 15 34 100.0 36 87.8 60 84.5
Marital Status 0.11
Married or living with somebody 16 47.1 32 78.1 46 64.8
Single 3 8.8 8 19.5 24 33.8
Missing 15 44.1 1 2.4 1 1.4
Employment Status 0.31
Employed 0 3 7.3 2 2.8
Non-employed 16 47.1 34 82.9 57 80.3
Missing 18 52.9 4 9.8 12 16.9
Contact history 0.70
Diagnosed as a contact 1 2.9 8 19.5 16 22.5
Not diagnosed as a contact 33 97.1 33 80.5 55 77.5
aThe chi-squared test was used to compare categorical variables by type of regimen, among those started on
treatment
https://doi.org/10.1371/journal.pone.0237787.t001
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Table 2. Disease characteristic among patients who started RR-TB treatment.
Treatment not started (n = 34) Treatment started (n = 112)
Short treatment regimen
(n = 41)
Individualized regimen
(n = 71)
p-Valuea
N % N % N %
Case definition 0.06
New 21 61.8 15 36.6 39 54.9
Previously treated 13 38.2 26 63.4 32 45.1
Previous TB regimen 0.02
First line drugs 18 52.9 22 46.3 28 39.4
Second line drugs 0 0 0 0 3 4.2
Unknown (missing) 16 47.1 19 46.3 40 56.3
BMI 0.17
< 18.5 kg/m2 2 5.9 22 53.7 46 64.8
> = 18.5 kg/m2 7 20.6 19 46.3 23 32.4
Unknown (missing) 25 73.5 0 2 2.8
Site of TB infection 0.90
Pulmonary 34 100.0 40 97.6 69 97.2
Extrapulmonary 0 1 2.4 2 2.8
Baseline smear 0.06
Positive 21 61.7 36 87.8 53 75.7
Negative 12 35.3 3 7.3 15 21.3
Unknown (missing) 1 2.9 2 4.9 3 4.23
Baseline culture 0.48
Positive 6 17.7 31 75.6 50 70.4
Negative 11 32.3 8 19.5 18 25.4
Unknown (missing) 17 50.0 2 4.9 3 4.2
Baseline symptoms 0.44
Symptomatic 13 38.2 41 100.0 70 98.6
Non symptomatic 21 61.8 0 1 1.4
Baseline Hearing lossb 0.85
No NA1 NA 18 43.9 26 36.6
Yes NA NA 21 51.2 28 39.4
Unknown (missing) NA NA 2 4.9 17 24.0
Extent of disease on chest radiograph 0.67
Severe 5 14.7 34 82.9 61 85.9
Non severe or normal 29 85.3 7 17.1 10 14.1
Pregnancy 0.72
No 19 95 19 86.4 42 91.3
Yes 1 5.0 3 13.6 4 8.7
Diabetes 0.12
No 33 97.1 41 100.0 67 94.4
Yes 1 2.9 0 4 5.6
Cardiovascular disease 0.12
No 33 97.1 41 100.0 67 94.4
Yes 1 2.9 0 4 5.6
aThe chi-squared test was used to compare categorical variables by type of regimen among those that started treatment.
bHearing assessment was done after the patient agreed to start the treatment
https://doi.org/10.1371/journal.pone.0237787.t002
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initially fluoroquinolone-resistant TB. Of these 39 patients, 32 (82.1%) were treated with the
individualized regimen. The proportion with initial fluoroquinolone-resistant TB was higher
among patients started on the individualized regimen (60.4% (32/53) vs 24.1% (7/29);
p = 0.002). Of 75 patients with second-line injectable DST results, 3 (4.0%) had TB resistant to
second-line injectables. All three patients were treated with the individualized regimen.
Application of adapted WHO 2016 criteria for choice of regimen
Of 112 patients that started treatment, 41 (36.6%) and 71 (63.4%) were treated with the short
and individualized regimen, respectively. The reasons provided (one reason per patient) for
starting the individualized regimen included: baseline hearing loss (20 patients, 28.2%), being
younger than 15 years (11 patients, 5.5%), pregnancy (4 patients, 5.6%), refusal to start treat-
ment with second-line injectables due to access issues (18 patients, 25.4%), previous treatment
with second-line TB drugs for longer than one month (3 patients, 4.2%), and initial
Table 3. Resistance pattern among patients who initiated treatment.
Short treatment regimen (n = 41) Individualized regimen (n = 71)
N % N %
Resistance to isoniazid
Resistant 14 45.2 32 60.4
katGa mutation 11 35.5 22 41.5
inhAa mutation 1 3.2 7 13.2
katG and inhA mutation 0 0 2 3.8
Phenotypic resistance (only) 2 6.5 1 1.9
Sensitive or wild type 17 54.8 21 39.6
Result missing 10 24.4 18 25.4
Resistance to pyrazinamide
Resistant 9 52.9 11 42.3
pncAa sequencing mutation 3 17.6 3 11.6
Phenotypic resistance (only) 6 35.3 8 30.7
Sensitive or wild type 8 47.1 15 57.7
Result missing 24 58.5 45 63.4
Resistance to fluoroquinolones
Resistant 7 24.1 32 60.4
gyrAa 7 24.1 24 45.3
gyrBa 0 1 1.9
gyrA + gyrB 0 2 3.8
Phenotypic resistance (only) 0 1 1.9
Sequencing resistance (only) 0 4 7.5
Sensitive or wild type 22 75.9 21 39.6
Result missing 12 29.3 18 25.4
Resistance to second line injectables
Resistant 0 3 6.4
Rrsa mutation 0 3 6.4
Phenotypic resistance(only) 0 0
Sensitive or wild type 28 68.3 44 93.6
Result missing 13 31.7 24 33.8
a KatG, InhA, pncA, GyrA, GyrB, rrs are specific bacillary’ genes, which mutations confer resistance to particular
tuberculosis drugs
https://doi.org/10.1371/journal.pone.0237787.t003
PLOS ONE Implementing drug resistant tuberculosis treatment guidelines in Kandahar, Afghanistan
PLOS ONE | https://doi.org/10.1371/journal.pone.0237787 August 21, 2020 8 / 17
fluoroquinolone resistance with no other reason (15 patients, 21.1%). Among patients with ini-
tially fluoroquinolone-resistant TB, seven were treated with the STR. Three women in late-
stage pregnancy preferred the STR. STR was also started in 15 (36.6%), five (12.2%), and one
(2.4%) patient presented with mild, moderate or severe hearing impairment respectively, as
registered on their baseline audiometry. All patients on the individualized regimen were
treated according to national and international (WHO) guidelines and received at least 4 likely
active TB drugs. The composition of the individualised regimen is shown in Table 4.
Tolerability
Table 5 reports frequency of AE episodes. Of patients on the STR and the individualized regi-
men, 15 (36.6%) and 31 (44.3%) had at least one AE reported (p = 0.46). In these 46 patients,
124 AE episodes were recorded: 61 (49.2%) were mild, 49 (39.5%) moderate and 14 (11.3%)
severe. None of AE was life-threatening. Fourteen severe AE were due to: hepatotoxicity (4),
peripheral neuropathy (6), anemia (1), thrombocytopenia (1), hearing loss (1), and gastrointes-
tinal toxicity (1). The culprit drugs for hepatoxicity were pyrazinamide (two patients), high-
Table 4. Drugs included in individualized regimens.
Drug N %
Bedaquilline 23 32.4
Delamanid 16 11.0
Clofazimine 55 77.5
Moxifloxacine 40 56.3
Levofloxacine 17 23.9
PAS 7 9.9
Cycloserine 28 34.4
Ethionamide 47 66.2
Linezolid 38 53.5
Capreomycin 2 2.8
https://doi.org/10.1371/journal.pone.0237787.t004
Table 5. Typology and grading of 124 reported adverse events.
Short treatment regimen Individualized regimen
Mild Moderate Severe Total Mild Moderate Severe Total
N % N %
Dermatological 1 1 0 2 5.7 8 4 0 12 13.5
Endocrine or metabolic 4 0 0 4 11.4 0 0 0 0 0
Gastrointestinal 7 5 0 12 34.3 15 6 1 22 24.7
Hematological 0 0 1 1 2.9 1 2 1 4 4.5
Hepatic 6 5 2 13 37.1 0 3 2 5 5.6
Musculoskeletal 0 0 0 0 0 6 1 0 7 7.9
Renal 0 0 0 0 0 0 4 0 4 4.5
Neurological 0 1 0 1 2.9 8 8 6 22 24.7
Hearing loss 0 0 1 1 2.9 1 3 0 4 4.5
Systemic hypersensitivity 1 0 0 1 2.9 1 1 0 2 2.2
Cardiological (QTFc)a 0 0 0 0 0 2 5 0 7 7.9
Total 19 12 4 35 100.0 42 35 10 89 100.0
aCorrected QT interval considered abnormal if > 500 ms or >60 ms increase from the baseline value
https://doi.org/10.1371/journal.pone.0237787.t005
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dose isoniazid (one patient) and bedaquiline (one patient). Linezolid caused all six episodes of
severe peripheral neuropathy as well as one episode of severe anemia. Culprit drugs were
stopped and regimens adapted. No patient had to definitively stop treatment and in none
more than one drug was changed. In patients with AE and without AE, 6 (26.1%) and 17
(73.9%) had an unfavorable treatment outcome (p = 0.01), respectively. One patient suffered
from idiopathic thrombocytopenia while in another patient gastrointestinal symptomatology
was related to food poisoning.
Treatment response
Four patients on RR-TB treatment were transferred to the drug-sensitive TB programme
because results from the reference laboratory showed rifampicin-susceptible TB on FL-LPA
and Xpert MTB/RIF (genome sequencing ongoing). Their outcomes were not included in the
analysis. Of the remaining, RR-TB treatment outcomes were known for 77 (71.3%) patients,
while 31 (28.7%) patients were still on treatment at the end of the study period. In patients on
the STR and the individualized regimen, four-month smear conversion was achieved in 28
(96.6%) and 32 (97.9%), respectively, and six-month smear conversion in 29 (100%) and 46
(97.9%), respectively (Fig 2). In patients on STR and individualized regimen, four-month cul-
ture conversion was achieved in 22 (84.6%) and 37 (88.1%), and six-month culture conversion
in 25 (96.2%) and 41 (97.6%), respectively. The median time to smear conversion was 51.5
days (IQR 27–63) for the STR and 53 days (IQR 43–75.5) for the individualized regimen. The
median time to culture conversion was 61.5 days (IQR 50.5–99.5) for the STR and 77.5 days
(IQR 53–95) for the individualized regimen. Time to smear conversion (p = 0.34) or culture
conversion (p = 0.77) was similar for both regimens (Fig 2).
Favorable treatment outcomes were achieved among 79.8% and 63.6% in patients receiving
the STR and the individualized regimen, respectively (Table 6). Eleven (14.3%) patients died:
five died due to a co-morbidity, four died after stopping treatment but before being declared
LFU, one died due to TB meningitis, and for five patient the cause of death was not recorded.
No patient died due to AE. Excluding those LFU, mortality was more frequent in patients
treated with the individualized regimen (26.3% 10/38 vs 3.7% (1/27); p = 0.02) No patient
developed treatment failure. Among seven patients treated with the STR and with initially flu-
oroquinolone-resistant TB three (49.9%) were cured, one died (14.3%) and three (49.9%) were
LFU. All three pregnant women treated with the STR were cured and were without complica-
tions among the mothers or their infants.
Patients with initial resistance to fluoroquinolones and/or SLIJ had an almost four times
higher risk of experiencing an unfavorable outcome (vs susceptible to both or without DST
result; aHR 3.77, 95%CI 1.53–9.27; p = 0.004). Patients with severe disease on chest radiogra-
phy at baseline were 77% less at risk of having an unfavourable outcome (versus normal or
non-severe disease; aHR 0.23, 95%CI 0.08–068; p = 0.002). The choice of treatment regimen
(aHR 1.14, 95%CI 0.42–3.06; p = 0.79) was not correlated with having an unfavorable outcome
(Table 7).
Discussion
This study describes how WHO criteria for enrolment on either the STR or the individualized
long regimen were translated to the reality of the RR-TB program in Kandahar, Afghanistan.
Among 112 patients who started treatment 41 (36.6%) were on the STR while 71 (63.4%)
received an individualized long regimen. We used adapted WHO criteria for STR eligibility in
a flexible manner [6]. To not delay treatment while waiting for fluoroquinolone DST results,
patients were offered to start the STR if they had no other exclusion criteria. If DST results
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were not obtained, due to logistical constraints or an inadequate quality of the sputum sample,
STR exclusion criteria could not be fully assessed. Moreover, patient’s preferences and the
interplay between different clinical criteria were considered. We treated ten patients with STR
which would have been excluded from this regimen if WHO criteria would have been used
more strictly (seven with fluoroquinolone resistance and three pregnant women). Also, a large
proportion of patients treated with the second-line injectable containing STR had baseline
hearing impairment. They were treated with the STR either because impairment was mild
with conductive hearing loss, or because patients insisted to be treated for a shorter duration.
On the other hand, of 71 treated with the individualized regimen, 18 (25.3%) were eligible for
the STR but preferred the injectable-free long regimen. They were unable to commit to daily
clinic visits for injectables administration. Community-based provision of TB care, including
Fig 2. Kaplan-Meier estimates of time to smear and culture conversion. Smear and culture conversion are
considered as at least one negative result following positive baseline results and not followed by smear or culture
reversion during treatment.
https://doi.org/10.1371/journal.pone.0237787.g002
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the administration of injectables, has proven to be effective and acceptable in other settings
[18, 19] but was not feasible in our setting as it was no safe to travel outside the city limits of
Kandahar. Our consideration for patient’s preferences when choosing a regimen is coherent
with the 2019 WHO recommendation [20]. If we would used the WHO criteria more strictly,
only 33 (29.5%) patients would be treated with the STR. The choice corresponded in 65 (58%)
patients with the WHO criteria. Besides medical criteria also the patients’ preferences, logistics
and security constraints had to be taken into account.
Despite a high prevalence of fluoroquinolone resistance (47.6%) in our study population,
comparable to 52.1% reported in neighboring Baluchistan (Pakistan) [21], 70.1% of patients
were treated successfully. Treatment success was 79.8% in patients treated with the STR. Glob-
ally the success rate among patients treated for RR-TB is 55% [1], while the WHO target for
RR-TB treatment success is set at>75% [1]. We reported 47.7% treatment success in patients
with fluoroquinolone-resistant TB and treated with the individualized regimen. Globally the
success rate for extensively resistant TB is 34% [1]. The proportion LFU was 18.2% and 13.6%
in those treated with the STR and individualized regimen, respectively. This contrasts with
findings from the recent meta-analysis, which showed that patients treated with the STR were
less likely to be LFU (4.2% vs 14.6% in those treated with an individualized regimen) [22].
More than half of our patients came from outside Kandahar. Besides the requirement of daily
clinic visits for the administration of an injection, it is likely that contextual factors and cultural
barriers contributed to high LFU rates in war-torn Kandahar [23]. Mortality was higher
among those treated with the individualized regimen, which is probably explained by the
much higher frequency of baseline fluoroquinolone resistance in this cohort and concurrent
co-morbidities. Indeed, initial fluoroquinolone resistance was a strong predictor of having an
unfavorable outcome, which is coherent with other studies [10, 21, 26–30]. After adjusting for
initial fluoroquinolone resistance, severity of disease on chest radiography, and other con-
founders, the choice of regimen was not correlated with having an unfavorable outcome. How-
ever, our sample size might not have been large enough to detect a difference if there was one.
Moreover, our study was not designed to compare the effectiveness of both regimens.
Both regimens were bacteriologically very effective. No patient developed treatment failure.
Many patients had one or more known risk factors for delayed conversion [8, 24–27]. Despite
47.6% initially fluoroquinolone-resistant TB, a poor nutrition status in about half of our
patients, and over 80% with advanced disease on chest radiography, almost all patients
achieved six-month smear conversion. Six-month culture conversion was similarly high in
Table 6. Treatment outcome (n = 77).
Regimen Short treatment regimen (n = 33)a Individualized regimen (n = 44)b
Treatment outcome N % N %
Cured 26 79.8 21 47.7
Completed 0 0.0 7 15.9
Death 1 3.0 10 22.7
Treatment failure 0 0.0 0 0.0
Lost to follow-up 6 18.2 6 13.6
Transfer out 0 0.0 0 0.0
aAt the time of analysis 5 patients were still on treatment and 3 patients were excluded from DR-TB cohort (and
treatment) due to discrepancy in rifampicin resistance test results
bAt the time of analysis 26 patients were still on treatment and 1 patient was excluded from DR-TB cohort (and
treatment) due to discrepancy in rifampicin resistance test results
https://doi.org/10.1371/journal.pone.0237787.t006
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Table 7. Associations of participants characteristics with favourable and unfavourable outcomes (death and lost to follow-up).
Exposure variables Total Favorable Outcomes Unfavorable outcomes HR (95%CI)a p-value AHRb p-value
(95% CI)
(N = 67)
District
Kandahar 40 (52%) 31 (57.4%) 9 (39.1%) 0.58 (0.25–1.35) 0.21 0.82 (0.34–2.02) 0.67
Other 37 (48%) 23 (42.6%) 14 (60.9%) Ref
Age (years)
< 15 years 11 (14.3%) 8 (14.8%) 3 (13%) Ref Ref NA NA
> = 15 years 66 (85.7%) 46 (85.2%) 20 (87%) 0.99 (0.29–3.35) 0.99
Gender
Male 34 (44.2%) 24 (44.4%) 10 (43.5%) Ref Ref NA NA
Female 43 (55.8%) 30 (55.6%) 13 (56.5%) 0.97 (0.43–2.23) 0.96
Marital status
With partner 55 (71.4%) 41 (75.9%) 14 (60.9%) Ref Ref NA NA
No partner 22 (28.6%) 13 (24.1%) 9 (39.1%) 1.73 (0.75–4.01) 0.20
Employment
Employed 4 (5.2%) 2 (3.7%) 2 (8.7%) Ref
Unemployed 69 (89.6%) 51 (94.4%) 18 (78.3%) 0.31 (0.07–1.33) 0.11 NA NA
Missing 4 (4.2%) 1 (1.9%) 3 (13%) NA
Previous treatment
New 42 (54.5%) 28 (51.9%) 14 (60.9%) 0.66 (0.28–1.54) 0.34 NA NA
Previously treated 35 (45.5%) 26 (48.1%) 9 (39.1%) Ref
Regimen
Short Course 33 (42.9%) 26 (48.2%) 7 (30.4%) Ref
Individualized 44 (57.1%) 28 (51.8%) 16 (69.6%) 1.32 (0.52–3.36) 0.56 1.14 (0.42–3.06) 0.79
Radiological severity
Normal/not severe 11 (14.3%) 5 (9.3%) 6 (26.1%) Ref Ref Ref 0.007
Severe 66 (85.7%) 49 (90.7%) 17 (73.9%) 0.33 (0.13–0.85) 0.02 0.23 (0.08–0.68)
BMI (kg/m2) (n = 73)
< 18.5 28 (36.4%) 21 (38.9%) 7 (30.4%) Ref Ref NA NA
> = 18.5 47 (61%) 31 (57.4%) 16 (69.6%) 1.36 (0.56–3.32) 0.45
Missing 2 (2.6%) 2 (3.7%) NA
Baseline smear
Negative/no result 8 (10.4%) 5 (9.3%) 3 (13%) Ref Ref NA NA
Positive 69 (89.6%) 49 (90.7%) 20 (87%) 0.59 (0.18–2.03) 0.60
Baseline culture
Negative/no result 15 (19.5%) 10 (18.5%) 5 (21.7%) Ref Ref NA NA
Positive 62 (80.5%) 44 (81.5%) 18 (78.3%) 0.71 (0.26–1.91) 0.49
Diabetes
No 2 (2.9%) 53 (98.2%) 22 (95.7%) Ref Ref NA NA
Yes 68 (97.1%) 1 (1.9%) 1 (4.3%) 2.22 (0.30–16.61) 0.46
Resistance to fluoroquinolonec
No 28 (48.3%) 25 (60.9%) 3 (17.7%) Ref Ref
Yes 30 (51.7%) 16 (39.1%) 14 (82.3%) 4.2 (1.19–14.6) 0.03 3.77 (1.53–9.27) 0.004
a Hazard ratio (univariate Cox analysis)
b Adjusted Hazard Ratio (adjusted for all variables listed in the table)
c There were three patients with concomitant resistance of fluoroquinolone and SLIJ and none of the patients had isolated SLIJ resistance
https://doi.org/10.1371/journal.pone.0237787.t007
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both treatment regimens. Our findings compare well with those from other studies, reporting
6-month conversion rates between 87%-98% [8, 24–27].
Overall, RR-TB treatment was well tolerated and the frequency of AE was lower than in
other studies [22]. Not a single life-threatening adverse event was reported. The most frequent
severe adverse event was peripheral neuropathy, mostly related to the use of linezolid at 600
mg per day. An even higher dose of linezolid, a component of a highly effective short all-oral
regimen that was recently tested in patients with fluoroquinolone-resistant TB or complicated
multi drug resistant TB [28], would require more frequent monitoring, which seems not feasi-
ble in our setting with compromised access to care. Future research should prioritize the devel-
opment of a tolerable short all-oral RR-TB treatment regimen, also effective in patients with
fluoroquinolone-resistant TB, and that can be administered regardless of age or pregnancy
status.
The majority of our patients were females of child bearing age (60.3%), which contrasts
with the higher proportion of males in global TB cohorts. A similar relatively high proportion
of female patients was reported in neighboring Pakistan [10, 21]. This may be explained by the
traditional role of women, who spend more time indoors and are the main caregivers of sick
family members. Overall, one fifth of patients was diagnosed through systematic and repetitive
screening among household contacts. Such approach is particularly important in contexts with
a high TB burden among children and women, especially when cultural and gender barriers
result in diagnostic delay [29, 30]. Among 112 patients on treatment, 16 (14.3%) were children
(< 15 years old). Globally 3% of all RR/MDR-TB cases are children, as only 3–4% of children
with RR-TB are being diagnosed and put on treatment [31]. Our cohort displayed a five-fold
higher proportion of children, which may be explained by systematic household contact trac-
ing [32]. In other studies, between 0.2% -11.2% of children were diagnosed with RR-TB disease
after RR-TB household contact screening [33–39].
The Afghanistan National Tuberculosis Control Programme has successfully decentralized
drug-susceptible TB care since 2005 [40, 41], but decentralization of RR-TB care is still in
progress. Of 146 patients diagnosed with RR-TB, 60.9% came from outside Kandahar as
RR-TB care was not available in their place of origin. We observed that a high proportion of
those eligible refused RR-TB treatment. Others died before starting treatment. Reasons for
refusal need to be explored further. The high frequency of pre-treatment attrition is a major
public health problem as it contributes to continuous RR-TB transmission in communities
and results in a high mortality among those not started on treatment. Decentralization of
RR-TB care reduces the treatment gap and increases retention in care [42]. Integration of
RR-TB care into primary health care services in conflict settings was described as feasible [43]
and could be a possible approach for the country in the future. Furthermore, community
based models of care, including administration of the injectable by a family member, have
been described and could be adapted to the context of Afghanistan, if security allows it [44].
This is the first RR-TB study from Afghanistan. Our programme data show the reality of
RR-TB care in Kandahar. However, this study also has several limitations. Due to a small sam-
ple size we were able to identify only those predictors that were strongly correlated with having
an unfavorable outcome, while weaker correlations may have been missed. This retrospective
study relied on routinely collected data, which was not complete for all the variables. Probably
minor adverse events were not systematically encoded in the electronic medical files. Further-
more, baseline DST results were missing for a substantial proportion of patients, which reflects
the reality of most RR-TB programmes today. The effect of initial resistance on treatment out-
comes should be addressed by future research. This study was not designed to assess reasons
of high pre-treatment attrition. Qualitative research studies should be planned to gather more
information on factors that could improve patient-centeredness. Our findings reflect the
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reality of Kandahar, but do not show the bigger picture of the RR-TB epidemic in Afghanistan.
Studies focusing on analysis of DR-TB care outcomes in specific age subgroups or those inves-
tigating the impact of social and economic factors need to be considered.
Conclusion
The translation and adaptation of formal TB treatment guidelines into practice is not straight-
forward in complex war-torn settings such as Kandahar. We have shown that a patient–cen-
tered approach resulted in the diagnosis of RR-TB in vulnerable groups, such as children and
woman, and assured that patients received the regimen that suited them best. Even though cri-
teria for the choice of treatment regimen were not strictly implemented, outcomes of both the
STR and longer regimen were good. WHO now encourages countries to pilot the use of all-
oral RR-TB regimens under operational research conditions. In this setting the baseline resis-
tance pattern, demographic characteristics of the population, and barriers to adverse event
monitoring will need to be accounted for when designing such al-oral regimen.
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